Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Testicular Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
21 drugs · 23 active trials
0 drugs · 0 active trials
no drug at this stage
3 drugs · 2 active trials
Outside the funnel: Phase not stated 5. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carboplatin | Phase 3 | Phase 3 | 3 | 1 | 1 | 8 | 0 | — | — | 2003-08 |
| Cisplatin | Phase 3 | Phase 3 | 3 | 2 | 2 | 5 | 0 | — | — | Nov 3, 2003 |
| Cyclophosphamide | Phase 3 | Phase 3 | 1 | 1 | 2 | 10 | 0 | — | — | 1988-03 |
| Doxorubicin | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 2004-12 |
| Methotrexate | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 1988-03 |
| Prednisone | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 2004-12 |
| Vincristine | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 2004-12 |
| Cytarabine | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | Feb 29, 2012 |
| Dexamethasone | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | 2003-08 |
| Leucovorin | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | 2009-06 |
| Bleomycin | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Nov 3, 2003 |
| Daunorubicin | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Mercaptopurine | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Pegaspargase | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Thioguanine | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Blinatumomab | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Calaspargase Pegol | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Inotuzumab Ozogamicin | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Prednisolone | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Dasatinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2008-10 |
| Clofarabine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Feb 29, 2012 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.